Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.95 +1.09 (+1.21%)

Streaming Delayed Price Updated: 3:20 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

74 75 Next >

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

January 19, 2024

From AstraZeneca

Via Business Wire

Check Out What Whales Are Doing With AZN ↗

January 17, 2024

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

January 16, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry ↗

January 09, 2024

Via Benzinga

Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold ↗

January 15, 2024

Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value.

Via InvestorPlace

MarketBeat Week in Review – 1/8 - 1/12

January 13, 2024

Stocks drifted lower as the latest inflation numbers are dampening expectations for a rate cut; here are some of our top stories for your long weekend

Via MarketBeat

Topics ETFs Economy

Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst ↗

January 12, 2024

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...

Via Benzinga

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution

January 12, 2024

Via Investor Brand Network

Topics Intellectual Property

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗

January 12, 2024

There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.

Via Investor's Business Daily

Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense ↗

January 11, 2024

Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah...

Via Benzinga

AstraZeneca: Rebound in 2024 with double-digit earnings growth

January 11, 2024

AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition

Via MarketBeat

January 08, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

January 08, 2024

Via Investor Brand Network

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

January 08, 2024

EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END

Via FinancialNewsMedia

Are defensive sectors ready to outshine growth in 2024?

January 06, 2024

Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.

Via MarketBeat

4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

January 06, 2024

The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight.

Via The Motley Fool

Topics Stocks

Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada ↗

January 05, 2024

The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.

Via Benzinga

With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs ↗

January 05, 2024

Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price

Via Benzinga

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

January 04, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

January 04, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024 ↗

January 03, 2024

These are the undervalued and fundamentally strong dividend-paying stocks to buy for high total returns in the next 24 to 36 months.

Via InvestorPlace

VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today ↗

January 02, 2024

VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.

Via InvestorPlace

China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants ↗

January 02, 2024

Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD

Via Benzinga

Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗

December 31, 2023

Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program....

Via Talk Markets

2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer ↗

December 29, 2023

During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc.

Via Benzinga

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗

December 29, 2023

The major indexes boast big annual gains with the Dow at record highs.

Via Investor's Business Daily

Topics Stocks

Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 ↗

December 28, 2023

2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.

Via Benzinga

Why Is Blood Purification Focused CytoSorbents Trading Lower Today? ↗

December 28, 2023

CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the...

Via Benzinga

The Decline In Global Bond Yields Supports Stock Indices ↗

December 28, 2023

A decline in global bond yields is lending support to stocks on optimism that global central banks will start cutting interest rates next year.

Via Talk Markets

Topics Bonds

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.